Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors

Ehab Atallah, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.

Original languageEnglish (US)
Pages (from-to)S105-S112
JournalClinical Lymphoma and Myeloma
Volume7
Issue numberSUPPL. 3
DOIs
StatePublished - Mar 2007

Fingerprint

Protein-Tyrosine Kinases
Safety
United States Food and Drug Administration
Hypereosinophilic Syndrome
Drug Approval
Muscle Cramp
Philadelphia Chromosome
Gastrointestinal Stromal Tumors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Fatigue
Diarrhea
Imatinib Mesylate
Clinical Trials
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Dasatinib
Therapeutics

Keywords

  • Chronic myeloid leukemia
  • Gastrointestinal stromal tumors
  • Side effects

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. / Atallah, Ehab; Kantarjian, Hagop; Cortes, Jorge.

In: Clinical Lymphoma and Myeloma, Vol. 7, No. SUPPL. 3, 03.2007, p. S105-S112.

Research output: Contribution to journalArticle

Atallah, Ehab ; Kantarjian, Hagop ; Cortes, Jorge. / Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. In: Clinical Lymphoma and Myeloma. 2007 ; Vol. 7, No. SUPPL. 3. pp. S105-S112.
@article{d00569e2e78a4e39adea2c09eaec751c,
title = "Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors",
abstract = "Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.",
keywords = "Chronic myeloid leukemia, Gastrointestinal stromal tumors, Side effects",
author = "Ehab Atallah and Hagop Kantarjian and Jorge Cortes",
year = "2007",
month = "3",
doi = "10.3816/CLM.2007.s.010",
language = "English (US)",
volume = "7",
pages = "S105--S112",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors

AU - Atallah, Ehab

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2007/3

Y1 - 2007/3

N2 - Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.

AB - Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.

KW - Chronic myeloid leukemia

KW - Gastrointestinal stromal tumors

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=34249653546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249653546&partnerID=8YFLogxK

U2 - 10.3816/CLM.2007.s.010

DO - 10.3816/CLM.2007.s.010

M3 - Article

C2 - 17382019

AN - SCOPUS:34249653546

VL - 7

SP - S105-S112

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - SUPPL. 3

ER -